The US Food and Drug Administration (FDA) on Tuesday announced it will hold a public meeting on 16 May to evaluate ways to apply FDA’s benefit-risk framework throughout the human drug lifecycle and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results